Multicomponent meningococcal serogroup B vaccine (4CMenB; Bexsero®): A review of its use in primary and booster vaccination

BioDrugs

Volumn 27, Issue 3, 2013, Pages 263-274

  Carter, Natalie J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; PRIORIX TETRA; UNCLASSIFIED DRUG;

ADVERSE OUTCOME; AGE; ANTIBODY TITER; APPETITE; ARTHRALGIA; ARTICLE; BACTERIAL STRAIN; CROSS REACTION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEVER; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION RESISTANCE; INJECTION SITE REACTION; INJECTION SITE SWELLING; JUVENILE RHEUMATOID ARTHRITIS; MALAISE; MENINGOCOCCOSIS; MYALGIA; NAUSEA; NEISSERIA MENINGITIDIS; NONHUMAN; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HAZARD; PATHOLOGICAL CRYING; PRIORITY JOURNAL; SIDE EFFECT; SKIN INDURATION; SOMNOLENCE; UNSPECIFIED SIDE EFFECT; VACCINATION;

ADOLESCENT; ADULT; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; INFANT; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SERUM BACTERICIDAL ANTIBODY ASSAY;

EID: 84878559098     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.1007/s40259-013-0029-2     Document Type: Article

References (29)

1. National Foundation for Infectious Diseases. The changing epidemiology of meningococcal disease among U.S. children, adolescents and young adults. 2004. http://www.nfid.org/pdf/meningitis/FINALChanging-Epidemiology-of-Meningococcal- Disease.pdf. Accessed 11 Sep 2011.
2. Caugant DA, Maiden MCJ. Meningococcal carriage and disease: population biology and evolution. Vaccine. 2009;27(4):B64-70.
3. European Centre for Disease Prevention and Control. Surveillance of invasive bacterial diseases in Europe. 2008/09. http://ecdc.europa.eu/en/ publications/Publications/1107-SUR-IBD-2008-09.pdf. Accessed 4 Mar 2013.
4. Rosenstein NE, Perkins BA, Stephens DS, et al. Meningococcal disease. N Engl J Med. 2001;344(18):1378-88. (Pubitemid 32378394)
5. Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet. 2007;369(9580):2196-210. (Pubitemid 46977462)
6. Trotter CL, Ramsay ME. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. FEMS Microbiol Rev. 2007;31(1):101-7. (Pubitemid 46058826)
7. Novartis Vaccines. Meningococcal group C conjugate vaccine (Menjugate Kit®): UK prescribing information. 2012. http://www.medicines.org.uk/EMC/ medicine/16597/SPC/Menjugate+Kit/. Accessed 4 Mar 2013.
8. Pfizer Limited. Meningitec® in pre-filled syringe: UK prescribing information. 2011. http://www.medicines.org.uk/EMC/medicine/20747/SPC/ Meningitec+in+pre-filled+syringe/. Accessed 4 Mar 2013.
9. Novartis Vaccines and Diagnostics. Meningococcal group A, C, W135, and Y conjugate vaccine (Menveo®): EU prescribing information. 2012. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/001095/WC500090147.pdf. Accessed 4 Mar 2013.
10. EUVAC.net. Meningococcal vaccination (MenC) overview in European countries. http://www.euvac.net/graphics/euvac/vaccination/menc.html. Accessed 4 Mar 2013.
11. Gray SJ, Trotter CL, Ramsay ME, et al. Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the meningococcal reference unit. J Med Microbiol. 2006;55:887-96. (Pubitemid 43974695)
12. Cohn AC, Harrison LH. Meningococcal vaccines: current issues and future strategies. Drugs 2013. In press.
13. Granoff DM. Review of meningococcal group B vaccines. Clin Infect Dis. 2010;50(Suppl 2):S54-65.
14. Lucidarme J, Comanducci M, Findlow J, et al. Characterization of fHbp, nhba (gna2132), nadA, porA, sequence type (ST), and genomic presence of IS1301 in group B meningococcal ST269 clonal complex isolates from England and Wales. J Clin Microbiol. 2009;47(11):3577-85.
15. Donnelly J, Medini D, Boccadifuoco G, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA. 2010;107(45):19490-5.
16. Pizza M, Scarlato V, Masignani V, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science. 2000;287(5459):1816-20. (Pubitemid 30143965)
17. Fletcher LD, Bernfield L, Barniak V, et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun. 2004;72(4):2088-100. (Pubitemid 38419922)
18. Novartis Vaccines and Diagnostics. Meningococcal group B vaccine (Bexsero®) suspension for injection: EU summary of product characteristics. 2012. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product- Information/human/002333/WC500137881.pdf. Accessed 13 Feb 2013.
19. Findlow J, Borrow R, Snape MD, et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis. 2010;51(10):1127-37.
20. Snape MD, Dawson T, Oster P, et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J. 2010;29(11):e71-9.
21. Vesikari T, Esposito S, Prymula R, et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomized trials. Lancet. 2013. doi: 10.1016/S0140-6736(12) 61961-8.
22. Gossger N, Snape MD, Yu L-M, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA. 2012;307(6):573-82.
23. Santolaya ME, O'Ryan ML, Valenzuela MT, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet. 2012;379(9816):617-24.
24. Kimura A, Toneatto D, Kleinschmidt A, et al. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Clin Vaccine Immunol. 2011;18(3):483-6.
25. Prymula R, Vesikari T, Esposito S, et al. Catch-up vaccination of healthy toddlers with an investigational multicomponent meningococcal serogroup B vaccine (4CMenB):exploration of a two-dose schedule [poster]. 29th European Society for Paediatric Infectious Diseases Conference; 7-11 June 2011; The Hague.
26. Vesikari T, Prymula R, Liese J, et al. Booster dose at 12 months of an investigational meningococcal serogroup B vaccine (4CMenB) in healthy toddlers previously primed at 2, 4, 6 months [poster]. 29th European Society for Paediatric Infectious Diseases Conference; 7-11 June 2011; The Hague.
27. Vogel U, Taha M-K, Vazquez JA, et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis. 2013. doi: 10.1016/S1473-3099(13) 70006-9.
28. Beeretz I, MD S, A F, et al. Reactogenicity and safety of multicomponent meningococcal serogroup B vaccine (4CMenB) administered with or without routine infant vaccinations in different schedules [poster]. 29th European Society for Paediatric Infectious Diseases Conference; 7-11 June 2011; The Hague.
29. Novartis. Novartis candidate vaccine Bexsero® shows significant potential in providing broad coverage against meningococcal serogroup B infections. 2011. http://www.novartis.com/newsroom/media-releases/en/2011/ 1522283.shtml. Accessed 28 Mar 2013.